Novozymes A/S (CPH:NSIS.B)
408.00
-0.40 (-0.10%)
Oct 23, 2025, 4:59 PM CET
Novozymes Revenue
Novozymes had revenue of 1.02B EUR in the quarter ending June 30, 2025, with 4.12% growth. This brings the company's revenue in the last twelve months to 4.10B, up 34.50% year-over-year. In the year 2024, Novozymes had annual revenue of 3.83B with 59.58% growth.
Revenue (ttm)
4.10B EUR
Revenue Growth
+34.50%
P/S Ratio
6.21
Revenue / Employee
387.25K EUR
Employees
10,582
Market Cap
189.96B DKK
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.83B | 1.43B | 59.58% |
| Dec 31, 2023 | 2.40B | 42.38M | 1.80% |
| Dec 31, 2022 | 2.36B | 348.99M | 17.36% |
| Dec 31, 2021 | 2.01B | 128.32M | 6.82% |
| Dec 31, 2020 | 1.88B | -41.10M | -2.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SP Group | 2.90B |
| H+H International | 2.77B |
| Flügger group | 2.27B |
| RIAS A/S | 320.36M |
| Hove A/S | 191.99M |
| Scandinavian Investment Group | 25.10M |
Novozymes News
- 2 months ago - Novonesis A/S (NVZMF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Novonesis: Industry Leader With Defensive Characteristics And Solid Growth - Seeking Alpha
- 5 months ago - Novonesis A/S (NVZMF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 8 months ago - Novonesis A/S (NVZMF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 months ago - Top 3 global stocks poised for 40% gains by 2025 - Invezz
- 1 year ago - Novonesis A/S (NVZMF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Novonesis: Underperformance In Price, But Now I'm Buying (Rating Upgrade) - Seeking Alpha
- 1 year ago - Novozymes A/S (NVZMF) Q2 2024 Earnings Call Transcript - Seeking Alpha